Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 May;8(5):416-427.
doi: 10.1016/S2215-0366(21)00084-5. Epub 2021 Apr 6.

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Affiliations
Comparative Study

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records

Maxime Taquet et al. Lancet Psychiatry. 2021 May.

Abstract

Background: Neurological and psychiatric sequelae of COVID-19 have been reported, but more data are needed to adequately assess the effects of COVID-19 on brain health. We aimed to provide robust estimates of incidence rates and relative risks of neurological and psychiatric diagnoses in patients in the 6 months following a COVID-19 diagnosis.

Methods: For this retrospective cohort study and time-to-event analysis, we used data obtained from the TriNetX electronic health records network (with over 81 million patients). Our primary cohort comprised patients who had a COVID-19 diagnosis; one matched control cohort included patients diagnosed with influenza, and the other matched control cohort included patients diagnosed with any respiratory tract infection including influenza in the same period. Patients with a diagnosis of COVID-19 or a positive test for SARS-CoV-2 were excluded from the control cohorts. All cohorts included patients older than 10 years who had an index event on or after Jan 20, 2020, and who were still alive on Dec 13, 2020. We estimated the incidence of 14 neurological and psychiatric outcomes in the 6 months after a confirmed diagnosis of COVID-19: intracranial haemorrhage; ischaemic stroke; parkinsonism; Guillain-Barré syndrome; nerve, nerve root, and plexus disorders; myoneural junction and muscle disease; encephalitis; dementia; psychotic, mood, and anxiety disorders (grouped and separately); substance use disorder; and insomnia. Using a Cox model, we compared incidences with those in propensity score-matched cohorts of patients with influenza or other respiratory tract infections. We investigated how these estimates were affected by COVID-19 severity, as proxied by hospitalisation, intensive therapy unit (ITU) admission, and encephalopathy (delirium and related disorders). We assessed the robustness of the differences in outcomes between cohorts by repeating the analysis in different scenarios. To provide benchmarking for the incidence and risk of neurological and psychiatric sequelae, we compared our primary cohort with four cohorts of patients diagnosed in the same period with additional index events: skin infection, urolithiasis, fracture of a large bone, and pulmonary embolism.

Findings: Among 236 379 patients diagnosed with COVID-19, the estimated incidence of a neurological or psychiatric diagnosis in the following 6 months was 33·62% (95% CI 33·17-34·07), with 12·84% (12·36-13·33) receiving their first such diagnosis. For patients who had been admitted to an ITU, the estimated incidence of a diagnosis was 46·42% (44·78-48·09) and for a first diagnosis was 25·79% (23·50-28·25). Regarding individual diagnoses of the study outcomes, the whole COVID-19 cohort had estimated incidences of 0·56% (0·50-0·63) for intracranial haemorrhage, 2·10% (1·97-2·23) for ischaemic stroke, 0·11% (0·08-0·14) for parkinsonism, 0·67% (0·59-0·75) for dementia, 17·39% (17·04-17·74) for anxiety disorder, and 1·40% (1·30-1·51) for psychotic disorder, among others. In the group with ITU admission, estimated incidences were 2·66% (2·24-3·16) for intracranial haemorrhage, 6·92% (6·17-7·76) for ischaemic stroke, 0·26% (0·15-0·45) for parkinsonism, 1·74% (1·31-2·30) for dementia, 19·15% (17·90-20·48) for anxiety disorder, and 2·77% (2·31-3·33) for psychotic disorder. Most diagnostic categories were more common in patients who had COVID-19 than in those who had influenza (hazard ratio [HR] 1·44, 95% CI 1·40-1·47, for any diagnosis; 1·78, 1·68-1·89, for any first diagnosis) and those who had other respiratory tract infections (1·16, 1·14-1·17, for any diagnosis; 1·32, 1·27-1·36, for any first diagnosis). As with incidences, HRs were higher in patients who had more severe COVID-19 (eg, those admitted to ITU compared with those who were not: 1·58, 1·50-1·67, for any diagnosis; 2·87, 2·45-3·35, for any first diagnosis). Results were robust to various sensitivity analyses and benchmarking against the four additional index health events.

Interpretation: Our study provides evidence for substantial neurological and psychiatric morbidity in the 6 months after COVID-19 infection. Risks were greatest in, but not limited to, patients who had severe COVID-19. This information could help in service planning and identification of research priorities. Complementary study designs, including prospective cohorts, are needed to corroborate and explain these findings.

Funding: National Institute for Health Research (NIHR) Oxford Health Biomedical Research Centre.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests SL is an employee of TriNetX. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
Kaplan-Meier estimates for the incidence of major outcomes after COVID-19 compared with other RTIs Shaded areas are 95% CIs. For incidences of first diagnoses, the number in brackets corresponds to all patients who did not have the outcome before the follow-up period. For diagnostic subcategories, see appendix (pp 8–10). RTI=respiratory tract infection.
Figure 2
Figure 2
Kaplan-Meier estimates for the incidence of major outcomes after COVID-19 comparing patients requiring hospitalisation with matched patients not requiring hospitalisation, and comparing those who had encephalopathy with matched patients who did not have encephalopathy 95% CIs are omitted for clarity but are shown in the appendix (p 23). For incidences of first diagnoses, the total number corresponds to all patients who did not have the outcome before the follow-up period. The equivalent figure showing the comparison between patients with intensive therapy unit admission versus those without is presented in the appendix (p 22).

Comment in

  • Neuropsychiatric disorders and COVID-19.
    Charlton E, Nainar F, Reyes-Beaman S. Charlton E, et al. Lancet Psychiatry. 2021 Jul;8(7):563. doi: 10.1016/S2215-0366(21)00177-2. Lancet Psychiatry. 2021. PMID: 34147172 Free PMC article. No abstract available.
  • Neuropsychiatric disorders and COVID-19.
    Finsterer J. Finsterer J. Lancet Psychiatry. 2021 Jul;8(7):563-564. doi: 10.1016/S2215-0366(21)00172-3. Lancet Psychiatry. 2021. PMID: 34147173 Free PMC article. No abstract available.
  • Neuropsychiatric disorders and COVID-19.
    Burchill E, Rogers JP, Needham D, Lang AE, Nicholson TR. Burchill E, et al. Lancet Psychiatry. 2021 Jul;8(7):564-565. doi: 10.1016/S2215-0366(21)00178-4. Lancet Psychiatry. 2021. PMID: 34147174 Free PMC article. No abstract available.
  • Neuropsychiatric disorders and COVID-19 - Authors' reply.
    Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. Taquet M, et al. Lancet Psychiatry. 2021 Jul;8(7):565-566. doi: 10.1016/S2215-0366(21)00202-9. Lancet Psychiatry. 2021. PMID: 34147175 Free PMC article. No abstract available.
  • Neurologische und psychische Leiden nach COVID-19 sehr häufig.
    Hasan A. Hasan A. MMW Fortschr Med. 2021 Aug;163(14):26-27. doi: 10.1007/s15006-021-0090-6. MMW Fortschr Med. 2021. PMID: 34370235 Free PMC article. Review. German. No abstract available.

References

    1. Rogers JP, Chesney E, Oliver D. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611–627. - PMC - PubMed
    1. Ellul MA, Benjamin L, Singh B. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767–783. - PMC - PubMed
    1. Varatharaj A, Thomas N, Ellul MA. Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. Lancet Psychiatry. 2020;7:875–882. - PMC - PubMed
    1. Paterson RW, Brown RL, Benjamin L. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020;143:3104–3120. - PMC - PubMed
    1. Kremer S, Lersy F, Anheim M. Neurologic and neuroimaging findings in patients with COVID-19: a retrospective multicenter study. Neurology. 2020;95:e1868–e1882. - PubMed

Publication types

MeSH terms